Novartis Teams Up With Legend, Moving CAR-T Into Solid Tumors

The Swiss drug maker is licensing multiple DLL3-targeting CAR-Ts from the Chinese biotech, including one already in early clinical development, and will use its T-Charge manufacturing platform.

Novartis signed a licensing deal with Legend Biotech for its DLL3-directed CAR-T therapy candidates. • Source: Shutterstock

Novartis AG took another step toward catching up with its peers in the cell therapy space with a partnership with Legend Biotech Corp. to develop CAR-T cells for solid tumors, particularly lung and neuroendocrine cancers, with one of the licensed candidates already in the clinic.

Legend announced the deal on 13 November, through a subsidiary, whereby Novartis will pay it $100m up front plus clinical,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

More from Business